Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells.

[1]  P. Adamson,et al.  Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. , 1991, Cancer research.

[2]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[3]  A. Harris,et al.  Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide. , 1990, Cancer research.

[4]  T. Shimizu,et al.  Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine. , 1990, Leukemia research.

[5]  M. Masquelier,et al.  On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells. , 1990, Cancer research.

[6]  S. Kaye,et al.  Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. , 1989, Cancer research.

[7]  M. Luscombe,et al.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. , 1987, British Journal of Cancer.

[8]  J. Maybaum,et al.  Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine. , 1987, Cancer research.

[9]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[10]  R. Roberts,et al.  Different functional domains of the adenovirus E1A gene are involved in regulation of host cell cycle products , 1987, Molecular and cellular biology.

[11]  D. Poplack,et al.  Modulation of thiopurine cytotoxicity in the HL-60 cell line by physiological concentrations of hypoxanthine. , 1986, Cancer research.

[12]  F. Balis,et al.  Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. , 1985, Cancer research.

[13]  R. Meyn,et al.  6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. , 1984, Cancer research.

[14]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[15]  J. Maybaum,et al.  Unilateral chromatid damage: a new basis for 6-thioguanine cytotoxicity. , 1983, Cancer research.

[16]  D. Deen,et al.  Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. , 1983, Cancer treatment reports.

[17]  R. Riccardi,et al.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.

[18]  Lee Sh,et al.  The effects of inhibitors of DNA biosynthesis on the cytotoxicity of 6-thioguanine. , 1981 .

[19]  D. J. Adamson,et al.  Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. , 1975, Cancer research.

[20]  J. X. Khym.  An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers. , 1975, Clinical chemistry.

[21]  D. Tidd,et al.  A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. , 1974, Cancer research.

[22]  D. Tidd,et al.  Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. , 1974, Cancer research.

[23]  A. Paterson,et al.  Delayed expression of 6-mercaptopurine cytotoxicity toward HeLa cells. , 1974, Neoplasma.

[24]  E. Scholar,et al.  Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. , 1973, Cancer research.

[25]  H. H. Lloyd,et al.  Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. , 1970, Cancer chemotherapy reports.

[26]  W. Martin,et al.  Metabolism of 6-Mercaptopurine by Resistant Escherichia coli Cells , 1966, Journal of bacteriology.